U.S. Markets closed

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
86.00-0.75 (-0.86%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close86.75
Open86.00
Bid86.00 x 1100
Ask87.00 x 800
Day's Range84.75 - 86.78
52 Week Range67.68 - 181.83
Volume1,126,851
Avg. Volume1,193,898
Market Cap6.859B
Beta (5Y Monthly)1.55
PE Ratio (TTM)N/A
EPS (TTM)-7.11
Earnings DateAug 03, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est133.71
  • Why Is Sarepta Therapeutics (SRPT) Down 1.1% Since Last Earnings Report?
    Zacks

    Why Is Sarepta Therapeutics (SRPT) Down 1.1% Since Last Earnings Report?

    Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Sarepta Therapeutics to Present at Upcoming Investor Conferences
    GlobeNewswire

    Sarepta Therapeutics to Present at Upcoming Investor Conferences

    CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming virtual investor conferences: Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10 at 1:20 p.m. E.T.BofA Securities 2021 Napa BioPharma Virtual Conference on Wednesday, June 16 at 10:30 a.m. E.T. The presentations will be webcast liv

  • Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    GlobeNewswire

    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 28, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 6 individuals hired by Sarepta in May 2021. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received, in the aggregate, options to purchase 6,295 shares of Sarepta's common stock, and in the aggregate 2,950 restricted stock units (“RSUs”). The options have an exercise price of $75.65 per share, which is equal to the closing price of Sarepta's common stock on May 28, 2021 (the “Grant Date”). One-fourth of the shares underlying each employee’s option will vest on the one-year anniversary of the Grant Date and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates. One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting date. About Sarepta TherapeuticsSarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook. Internet Posting of InformationWe routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us. Source: Sarepta Therapeutics, Inc. Investor Contact: Ian Estepan, 617-274-4052iestepan@sarepta.com Media Contact: Tracy Sorrentino, 617-301-8566tsorrentino@sarepta.com